Mitigating Risks In Countries With Poor IP Protection
Life Science Leader, a business magazine for executives working in the life sciences, pharmaceutical, biopharmaceutical, and medical device industries, wrote a feature story on Tim Hubbard's research on safeguarding R&D rights in risky countries. Hubbard is an assistant professor of management in the Mendoza College of Business.…
- Published
Life Science Leader, a business magazine for executives working in the life sciences, pharmaceutical, biopharmaceutical, and medical device industries, wrote a feature story on Tim Hubbard's research on safeguarding R&D rights in risky countries. Hubbard is an assistant professor of management in the Mendoza College of Business.
As Hubbard explains, downstream commercialization activities can counterbalance weak IP protection, thereby allowing a firm to profit from its investment. For example, a company may commercialize a product in one country, manufacture it in a nearby country, and conduct R&D in yet another country within the region. Investments rarely are so incremental or dispersed in the EU or U.S., according to Hubbard.
Related News & Stories
Faith
A common dedication to the truth is key to unity
Professor David Cloutier wrote an article for U.S. Catholic about friendship in communities with shared convictions.
U.S. Catholic
In the Classroom
New minors expand access to business education
More business minors are now available to all Notre Dame students—and new minors expand the educational offerings at Mendoza
Faculty in the Media
This company’s newspapers are ‘optimized for profit’ — for its hedge fund owner
Marketing's Vamsi Kanuri was featured in a McClatchy news story about the newspaper's sweeping layoffs and shift away from local reporting.
San.com